...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vascular Health and Risk Management >Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study
【24h】

Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of Middle East data from the OSCAR study

机译：基于依普罗沙坦的高血压疗法，收缩压和认知功能：来自OSCAR研究的中东数据分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Studies have indicated a relationship between hypertension and cognitive function. The possible effect of antihypertensive therapy on cognitive disorders is therefore a matter of interest. Materials and methods: The Observational Study on Cognitive function And SBP Reduction (OSCAR) was an open-label, multinational trial designed to evaluate the impact of eprosartan-based antihypertensive therapy on cognitive function in patients with essential hypertension. Eprosartan 600 mg/day for 6 months (with provision for additional medication as needed) was initiated in hypertensive subjects aged ≥50 years. A total of 853 patients in an intention-to-treat cohort from seven countries of the Middle East was identified for subgroup analysis. Results: Arterial blood pressure was reduced significantly ( P < 0.001) during the study: At the end of 6 months of eprosartan-based therapy, the mean (±SD) reduction from baseline was 32.1 ± 14.3/14.6.3 ± 8.6 mmHg ( P < 0.001). Mean pulse pressure was reduced by 18.3 ± 13.1 mmHg ( P < 0.0001 vs baseline). Blood pressure was normalized (systolic <140 mmHg and diastolic <90 mmHg) in 68.2% of patients. The overall mean Mini-Mental State Examination (MMSE) score after 6 months of eprosartan-based therapy was one-point higher than at baseline ( P < 0.001). MMSE score on completion of 6 months’ follow-up was either unchanged or increased from baseline in 793 (93%) individuals and decreased in 60 (7%). Factors associated with stability of or improvement in cognitive function included MMSE score at baseline, diastolic blood pressure (DBP) at baseline, and treatment-induced change in DBP. Conclusion: Results from the Middle East subgroup of OSCAR are supportive of the hypothesis that antihypertensive therapy based on angiotensin-receptor blocker therapy with eprosartan may be associated with preservation or improvement of cognitive function.
机译：背景：研究表明高血压与认知功能之间存在联系。因此，降压疗法对认知障碍的可能作用是一个令人关注的问题。材料和方法：认知功能和SBP降低的观察研究（OSCAR）是一项开放标签的跨国试验，旨在评估依普罗沙坦类降压药对原发性高血压患者认知功能的影响。在年龄≥50岁的高血压受试者中开始服用依普罗沙坦600毫克/天，持续6个月（根据需要提供其他药物）。鉴定了来自中东七个国家的意向性治疗队列中的853名患者，以进行亚组分析。结果：研究期间动脉血压显着降低（P <0.001）：依普罗沙坦为基础的治疗6个月结束时，相对于基线的平均降低（±SD）为32.1±14.3 / 14.6.3±8.6 mmHg（ P <0.001）。平均脉冲压力降低了18.3±13.1 mmHg（相对于基线P <0.0001）。在68.2％的患者中，血压正常（收缩期<140 mmHg，舒张期<90 mmHg）。依普罗沙坦治疗6个月后的总体平均最低精神状态检查（MMSE）得分比基线时高出一个百分点（P <0.001）。 793名个体（93％）完成6个月随访后的MMSE评分未发生变化或较基线有所增加，而60名患者（7％）则有所下降。与认知功能稳定性或认知功能改善相关的因素包括基线时的MMSE评分，基线时的舒张压（DBP）和治疗引起的DBP变化。结论：OSCAR中东亚组的结果支持以下假设，即基于依普沙坦的血管紧张素受体阻滞剂抗高血压治疗可能与认知功能的维持或改善有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号